Abeona Therapeutics Reports Third Quarter 2022 Financial Results
14. November 2022 07:30 ET
|
Abeona Therapeutics Inc.
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023 Company well-funded with expected cash...
Abeona Therapeutics Announces $35 Million Private Placement Financing
03. November 2022 07:31 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced today that it has entered into a securities purchase agreement to sell 7,065,946 shares of...
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
03. November 2022 07:30 ET
|
Abeona Therapeutics Inc.
Co-primary endpoint measuring >50% wound healing, other endpoints measuring >75% and complete wound healing at six months all met Co-primary endpoint measuring pain reduction at six months...
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
19. Oktober 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the database lock on October 18, 2022 for the pivotal Phase 3 VIITAL™ study of its...
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
04. Oktober 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the last patient has completed their 6-month follow-up visit in Abeona’s...
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
22. September 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a...
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
13. September 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel...
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
11. August 2022 07:30 ET
|
Abeona Therapeutics Inc.
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient...
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
20. Juli 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022...
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
06. Juni 2022 07:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is...